Renaissance Technologies’s Vivos Therapeutics VVOS Stock Holding History

Renaissance Technologies’s Portfolio VVOS Stock Details VVOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-39,279	Closed	-$122K	–	3803
2025 Q3	$122K	Buy	+39,279	New	+$178K	﹤0.01%	3231
2023 Q3	–	Sell	-1,342	Closed	-$17K	–	4154
2023 Q2	$17K	Sell	1,342 -2,214	-62%	-$21.7K	﹤0.01%	3793
2023 Q1	$30K	Buy	3,556 +2,916	+456%	+$63.8K	﹤0.01%	3761
2022 Q4	$6K	Buy	640 +124	+24%	+$1.81K	﹤0.01%	4057
2022 Q3	$8K	Hold	516	–	–	﹤0.01%	3959
2022 Q2	$17K	Buy	516 +80	+18%	+$3.32K	﹤0.01%	4135
2022 Q1	$29K	Buy	+436	New	+$28.5K	﹤0.01%	3975
2021 Q3	–	Sell	-768	Closed	-$95K	–	3881
2021 Q2	$95K	Buy	+768	New	+$125K	﹤0.01%	3364

Other funds holding VVOS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AWA

Acorn Wealth Advisors Grand Blanc, Michigan $343M AUM 15.24% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies's VVOS Position: Q4 2025 in Review

Renaissance Technologies sold out of Vivos Therapeutics (VVOS) in Q4 2025, closing a stake of 39,279 shares — an estimated $122K sold.

Renaissance Technologies first reported a position in VVOS in Q2 2021 and held it in 8 quarters. The position peaked at $122K in Q3 2025. 19 funds tracked by Wall St. Rank hold VVOS as of Q4 2025.

Renaissance Technologies reported no remaining Vivos Therapeutics position as of Q4 2025 after selling out during the quarter.
Renaissance Technologies sold 39,279 Vivos Therapeutics shares in Q4 2025, an estimated $122K.
Renaissance Technologies first reported a position in Vivos Therapeutics in Q2 2021 and held it in 8 quarters.
Renaissance Technologies's Vivos Therapeutics position peaked at $122K in Q3 2025.
19 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q4 2025.

Based on Renaissance Technologies's 13F filing for Q4 2025, filed 12 Feb 2026.